Integral Diagnostics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 1/6

Integral Diagnostics 2.56% cari getiri oranına sahip temettü ödeyen bir şirkettir.

Anahtar bilgiler

2.6%

Temettü verimi

0.02%

Geri Alım Getirisi

Toplam Hissedar Getirisi	2.6%
Gelecekteki Temettü Verimi	4.8%
Temettü Büyümesi	-0.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	427%

Son temettü ve geri alım güncellemeleri

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

Recent updates

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Apr 27 Synergies from the Capitol Health merger and regulation changes are expected to boost operating margins and revenue for Integral Diagnostics.

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

Feb 28

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: IDX 10 yıldan az bir süredir temettü ödüyor ve bu süre zarfında ödemeler dalgalı oldu.

Büyüyen Temettü: IDX şirketinin temettü ödemeleri artmış, ancak şirket yalnızca 9 yıldır temettü ödemiştir.

Piyasaya Karşı Temettü Getirisi

Integral Diagnostics Piyasaya Karşı Temettü Getirisi

IDX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (IDX)	2.6%
Pazarın Alt %25'i (AU)	2.5%
Pazarın En İyi %25'i (AU)	5.8%
Sektör Ortalaması (Healthcare)	1.8%
Analist tahmini (IDX) (3 yıla kadar)	4.8%

Önemli Temettü: IDX 'in temettüsü ( 2.56% ), Australian piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 2.49% ) daha yüksektir.

Yüksek Temettü: IDX 'in temettüsü ( 2.56% ), Australian piyasasındaki temettü ödeyenlerin en üst %25'ine ( 5.82% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 426.5% ) nedeniyle IDX 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Yüksek nakit ödeme oranı ( 172.9% ) nedeniyle, IDX 'un temettü ödemeleri nakit akışları tarafından yeterince karşılanmıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/11/19 06:52
Gün Sonu Hisse Fiyatı	2025/11/19 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Integral Diagnostics Limited 19 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Yeo	Barrenjoey Markets Pty Limited
Saul Hadassin	Barrenjoey Markets Pty Limited
Benjamin Brayshaw	Barrenjoey Markets Pty Limited

Integral Diagnostics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 1/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Final dividend increased to AU$0.04

First half dividend of announced

First half dividend of AU$0.025 announced

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Recent updates

New major risk - Dividend sustainability

Integral Diagnostics Limited, Annual General Meeting, Oct 31, 2025

Final dividend increased to AU$0.04

Price target increased by 7.1% to AU$3.34

Full year 2025 earnings released: EPS: AU$0.016 (vs AU$0.26 loss in FY 2024)

Consensus EPS estimates fall by 14%

New minor risk - Dividend sustainability

Upgraded MRI Licensing And Merger Synergies Will Fuel Future Success

Private Equity Players Reportedly Keep Close Tabs on Integral Diagnostics

Independent Non-Executive Chairman recently bought AU$79k worth of stock

Slammed 29% Integral Diagnostics Limited (ASX:IDX) Screens Well Here But There Might Be A Catch

First half dividend of announced

Price target decreased by 7.3% to AU$3.15

First half 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Integral Diagnostics Limited Appoints Manish Mittal to the Board as Radiologist Executive Director

Integral Diagnostics Limited Announces Company Secretary Changes

New major risk - Shareholder dilution

High number of new directors

Integral Diagnostics Limited Announces Board Appointments

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).

Integral Diagnostics Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Price target increased by 7.7% to AU$2.93

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

First half dividend of AU$0.025 announced

First half 2024 earnings: EPS misses analyst expectations

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Consensus EPS estimates fall by 12%

IDX™ Announces Appointment of Scott Paterson as Worldwide CFO

Integral Diagnostics Limited, Annual General Meeting, Nov 01, 2024

Integral Diagnostics Limited Announces Change of Company Secretary

Independent Non-Executive Director recently bought AU$258k worth of stock

Integral Diagnostics Limited Announces Resignation of Helen Kurincic as Director Effective 29 November 2023

Consensus EPS estimates fall by 11%

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Price target decreased by 7.5% to AU$3.05

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 27%

Integral Diagnostics Limited Appoints Toby Hall as Director

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Six Months Ended June 30, 2023, Payable on October 04, 2023

Full year 2023 earnings: EPS misses analyst expectations

Integral Diagnostics Limited Declares Fully Franked Final Dividend, Payable on October 04, 2023

Consensus EPS estimates fall by 16%

Integral Diagnostics Limited Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2023 earnings released: EPS: AU$0.069 (vs AU$0.051 in 1H 2022)

Integral Diagnostics Limited Announces Ordinary Dividend for the Six Months Ended December 31, 2022, Payable on April 4, 2023

Now 21% undervalued after recent price drop

Integral Diagnostics Limited to Report First Half, 2023 Results on Feb 17, 2023

Integral Diagnostics Limited to Report Fiscal Year 2023 Results on Aug 28, 2023

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Independent Non-Executive Director recently bought AU$114k worth of stock

Consensus forecasts updated

Now 22% undervalued after recent price drop

Integral Diagnostics Limited Declares Fully Franked Final Dividend for the Year Ended June 30, 2022, Payable on October 5, 2022

Full year 2022 earnings released

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to AU$3.65

Integral Diagnostics Limited Announces Appointment of Andrew Fay as an Independent Non-Executive Director

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Now 21% undervalued after recent price drop

Integral Diagnostics Limited (ASX:IDX) ) agreed to acquire Exact Radiology Pty Ltd for NZD 33.3 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Exact Radiology Pty Ltd for approximately AUD 39 million.

Now 21% undervalued

Executive Director recently bought AU$70k worth of stock

Consensus forecasts updated

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate